Business
Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022
New safety and immunogenicity data for the COVID-19-Influenza Combination vaccine candidate Phase 1/2 trial will be presentedNew data will be presented for
About this update from Novavax, Inc.
[{"type":"text","content":"New safety and immunogenicity data for the COVID-19-Influenza Combination vaccine candidate Phase 1/2 trial will be presentedNew data will be presented for Novavax' COVID-19 vaccine supporting its use as a homologous and heterologous booster in adults aged 18 and older and adolescents aged 12 through 17Updated Phase 3 PREVENT-19 data and new Study 307: Lot Consistency data will reinforce COVID-19 vaccine's benefits as an adult heterologous boosterGAITHERSBURG, Md., Oct. 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will present new safety and immunogenicity data from the first Phase 1/2 COVID-Influenza Combination (CIC) dose-finding trial evaluating its CIC vaccine candidate at the World Vaccine Congress (WVC) Europe, October 11 to 14, 2022. Data from the Phase 3 PREVENT-19 trial and from Study 307: Lot Consistency evaluating the protein-based Novavax COVID-19 vaccine (NVX-CoV2373) as a booster both in adults aged 18 and older and in adolescents aged 12 through 17 will also be presented.\n\"Data presented at WVC will show the continued momentum of our COVID-19 vaccine as a booster and also provide insight into our COVID-19-Influenza Combination vaccine candidate's immunogenicity, safety, and optimal dose,\" said Gregory Glenn, M.D., President of Research and Development at Novavax. \"Novavax is focused on developing innovative vaccines built on a well-established technology and we are committed to building a portfolio of best-in-class vaccines across multiple infectious disease areas.\"\nIn addition to the data presentations, Dr. Glenn will participate in a keynote panel to discuss the future of COVID-19 vaccines and next steps in addressing the pandemic.\nNovavax presentations during WVC Europe:Author \nPresentation title\nDetails\nGlenn, G \nThe future of COVID vaccination in the human population – What's the end game and how do we exit from the public health emergency?\nKeynote Panel\nOctober 12, 2022\n8:30 – 9:30am (CEST)\nÁñez, G\nBennett, C\nPaving the way for Protein: Novavax's COVID-19 Vaccine as a Booster, Variant-adapted\nOral Presentation \nOctober 12, 2022\n05:00 – 5:30pm (CEST)\nShinde, V\nUpdate on Novavax Investigational Influenza vaccine and COVID-19-INFLUENZA Combination Vaccine ...